(i.e., up to 2.5 years) data for upadacitinib 15 mg QD, upadacitinib 30 mg QD, MTX censored at rescue and adalimumab also censored at rescue [63]. In this analysis, the frequency of adverse events is presented as exposure-adjusted event rates. Unless otherwise indicated, the data ...